Canadian dermatologist predict that new therapies and devices will reshape the cosmetic treatment marketplace in 2010.
“The BOTOX COSMETIC® [botulinum toxin] market may be in for some competition,” says Dr. Vince Bertucci, an assistant professor at the University of Toronto in Toronto, past president of the Canadian Society for Dermtologic Surgery, and a dermatologist in private practice in the Toronto area. “The product Xeomin has been approved for medical use in Canada, and we may see off-label cosmetic use of the product in the near future.”
Xeomin is similar in efficacy and duration to BOTOX COSMETIC®, so the learning curve may not be so steep. Another possible future entry in the marketplace, Dysport, also has potential cosmetic applications. Clinicians will need to learn its unique administration techniques because Dysport, unlike Xeomin, will not be interchangeable with BOTOX COSMETIC®, notes Dr. Bertucci.